Connect with us


Press Release: PSYC Provides Shareholders with Key Corporate Updates and Highlights Objectives for 2023



LAS VEGAS, NV, Jan. 31, 2023 (GLOBE NEWSWIRE) — PSYC Corporation (OTC Pink Market: PSYC) (“PSYC”, “PSYC Corp” or the “Company”), parent company to Spotlight Media Corporation (“SMC” or the “wholly owned subsidiary”), a multimedia leader positioned at the intersection where all things psychedelics and cannabis converge, is pleased to provide its shareholders with an overview of recent key corporate updates along with insight into some of the prime objectives the Company is outlining for the year ahead.

Sacha G. Hebbert Joins the PSYC Board

As of this month, the Company is proud to have appointed Sacha G. Hebbert to its Board of Directors alongside PSYC CEO, David Flores and PSYC COO, Michael Berger. In addition to her appointment on the Company’s Board, Ms. Hebbert has also been appointed to the position of Chief Brand Officer (“CBO”) for PSYC Corp and will continue to maintain her position as Chief Operating Officer of the Company’s wholly owned subsidiary, Spotlight Media Corporation (“SMC”).

In her added role as CBO of the parent company, Ms. Hebbert will work in close collaboration with Mr. Flores and Mr. Berger with the ongoing development of PSYC’s brand and image as an evolving publicly traded multimedia leader for the emerging psychedelics sector, and with the objective of helping to identify opportunities to strengthen shareholder value.

Additionally, Ms. Hebbert will continue to play a pivotal leadership role with developing and implementing critical strategies designed to maximize the value of the Company’s current psychedelic-focused media assets operated under SMC such as Psychedelic Spotlight and Bonfire.

“My goal is to ensure that Psychedelic Spotlight continues to grow in domain authority. We’re currently ranked high amongst the top 5 psychedelic media outlets. By the end of this year, I see us in the number one position. Those investing in PSYC will be happy to know that Psychedelic Spotlight is well-positioned as a culture shaper and media partner to the entire B2C market. We continue to tap into the mainstreaming of psychedelics and attract a substantial and curious audience to our platform through provocative and informative content. We’re also building traffic toward Bonfire, our burgeoning community of psychedelic facilitators and seekers. These two platforms, together, create the perfect funnel for service and product providers and consumers in this growing market. By the end of next quarter, we should see a lot of action on our Bonfire platform as we align with strategic partnerships that expand concrete revenue generators.”

Integration of Newly Acquired Media Assets

In September of last year, the Company acquired Technical 420, On The Bids, and Mushroom Stocks from Technical420, LLC. In the months following the acquisition of these media assets, the Company dedicated considerable time to successfully integrating them into SMC as key revenue drivers for the Company.

These efforts, spearheaded by PSYC Chief Operating Officer and SMC Chief Revenue Officer, Michael Berger, have resulted in a steady increase in revenue generation for the Company, which it claims to be reflected as such in it’s soon-to-be-published 2022 annual disclosure and financials. During Q4 of 2022, the Company experienced its strongest revenue performance throughout all of 2022, with approximately $60K generated in gross revenue.

Plans through the first two quarters of 2023 are to continue to implement strategies that are primarily focused on expanding revenue generation capabilities of both Technical 420 and On The Bids. The Company contends that in the months following the acquisition, each of these platforms have emerged as primary revenue drivers for the Company by way of valuable investor and public relations-focused services provided to various publicly traded companies operating in thriving industries such as cannabis and mining and precious metals and where many companies are actively seeking the opportunities to enhance their exposure across the public markets – a key value point offered by Technical 420 and On The Bids.

Furthermore, in the months ahead, the Company plans to apply many of the elements that have have driven the success, from a revenue generation and client satisfaction standpoint, for both Technical 420 and On The Bids over into Mushroom Stocks, and particularly as public companies operating in the psychedelics sector are expected to begin to ramp investor awareness efforts back up throughout 2023.

PSYC COO Michael Berger said, “During the last quarter, our primary objectives have been centered around integrating the business units, finding synergies, and becoming cash flow positive. Since the completion of the acquisition, our websites have generated more than $100,000 of revenue and have secured approximately $75,000 in equity-based agreements. Although market conditions are challenging, we have been able to penetrate new verticals in a cost-efficient manner. We remain bullish on the cannabis and psychedelic industries and believe we have the assets and resources to achieve our primary objectives. Over the next year, we plan to establish Spotlight Media Corp as a media leader in several burgeoning industries and I am confident in our ability to do so.”

Updates on Bonfire and Psychedelic Finder 

Following more than 5 months of market testing on the current Bonfire platform, the Company, along with its partner in the project, Digital Acorn, Ltd., has opted to revisit the core fundamentals associated with the platform and with the intent of identifying and developing a more cost effective operations model for the platform, in addition to a more robust and refined monetization strategy that will be more effectively suited for scalability.

The pause on the current iteration of the platform coincides with the resignation of Jack Bunce this month who, over the last several months, had overseen the operations of the Bonfire platform.

In the coming weeks, the Company will work in collaboration with Digital Acorn to identify and select a new leadership team that will focus on successfully ushering Bonfire into the next phase of redevelopment.

The Company contends, however, that it remains cautiously optimistic as to the future potential of Bonfire citing valuable data and information it was successful in gathering throughout the market test phase that, according to the Company, reflects significant market interest in a platform designed with the intent of building a community centered around psychedelic integration.

With regard to Psychedelic Finder, the Company, along with its partners in the project, Nucleus Holding Inc., remain focused and committed to building out this platform which will be an online resource assisting those looking for treatment and care providers.

The companies, however, have agreed to push the official launch of the platform back into later in 2023 as they collectively focus on raising additional capital that will be required to bring some of the intricate details proposed for the platform to fruition.

The companies are intent on bringing to market a platform that goes far beyond what other, similar platforms, operating in this space currently offer.

The Company plans to continue to provide updates on the progress of both Bonfire and Psychedelic Finder in the weeks and months ahead.

Psychedelic Spotlight Continues to Thrive Under a Leaner, More Efficient Business Model

Coming into 2023, PSYC Management made the collective decision to implement various strategic updates to the operational structure of Psychedelic Spotlight. At the core of these updates, was developing a cost-effective plan that will continue to promote the growth of the platform, but under a leaner, and more efficient business model.

Over the course of 2022, PSYC was successful in establishing Psychedelic Spotlight as a top 5 media platform focused exclusively on psychedelics. According to the Company, this top 5 ranking is based on website performance data and analytics gathered from Google such as page views, site visits, and engagement, amongst other metrics.

The Company contends that these metrics play a vital role, as is typically the case with most media platforms, in the ability to monetize the platform through advertisement, sponsorship, and partnership opportunities, and views their current ranking as a competitive advantage in a marketplace that is becoming increasingly competitive.

Since implementing many of the aforementioned updates to the Psychedelic Spotlight business model at the start of the new year, which includes operating the platform with a leaner budget, the Company claims that the metrics tied to its website performance have not dropped off and in fact, the platform continues to hold steady amongst its top competitors and is even demonstrating growth in critical areas such as organic search. This, according to the Company, can be viewed as a demonstration of the success in some of the strategic and hyper-focused growth initiatives Psychedelic Spotlight Director of Marketing, Maria Holyanova, has recently implemented.

The Company plans to continue prioritizing the growth of Psychedelic Spotlight throughout 2023, and while it cannot offer any guarantees, the Company remains committed and highly optimistic in its objective of establishing it as the number one media platform for the emerging sector of psychedelics in the most reasonable time frame possible.

Closing Comments from PSYC CEO, David Flores

“In 2022, we witnessed the culmination of so much of the hard work we had been focused on over the previous two years in terms of developing PSYC into a formidable multimedia leader for psychedelics and other forward-thinking industries such as cannabis. We managed to grow Psychedelic Spotlight into a top 5 media platform for the growing sector of psychedelics, and we brought in new media assets that in addition to providing us with very valuable elements of diversification, have also created a steady, and much-needed revenue stream for us.

The objective here in 2023 is to take what we successfully accomplished last year and expand on it. Cracking the top 5 as a psychedelic’s media platform is a wonderful accomplishment, but make no mistake about it, we aspire to be number one. Bringing in assets that are revenue generating is, in my opinion, a huge step forward for us, but some revenue doesn’t equate to a viable path to profitability, so we’re laser focused on generating even more revenue.

From my perspective, all of these are very important fundamentals that we are meticulously moving into place as part of what we view as a much bigger objective for PSYC. They’re also lending to our ability to have real and very serious conversations related to potential value-driven partnership opportunities and even capital investment opportunities that we simply couldn’t have in years past.

Acquiring what is still, in my opinion, the best ticker symbol for a publicly traded company operating in the psychedelics sector (PSYC), was done so with the intention of developing PSYC into something much more than just another multimedia company operating in the psychedelics space. It was done with the intention of building PSYC into the multimedia company for psychedelics. And as we approach the 3-year mark of the commencement of this journey, this intention, from my perspective, and based on the fundamentals we have put into place, remains as attainable as ever.

There are still many challenges that lie ahead for us in order to earn the trust and credibility within the public markets that we believe is necessary to drive and deliver maximum shareholder value. But what I can assure you is that I, along with the newly formed board of directors and the incredibly talented and dedicated management team we have assembled for the Company, are working tirelessly each and every day to develop solutions that are aimed specifically at overcoming these challenges in the most reasonable manner and time frame possible.

Thank you to all the PSYC shareholders who continue to stand alongside us on this journey. We see you. We hear you, and we are committed to doing everything we can to return the value back to you that we believe you deserve.

About PSYC Corporation (OTC Pink Market: PSYC)
At PSYC Corporation we are integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.

PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, we believe investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.

We are dedicated to a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future.

About Spotlight Media Corporation

Spotlight Media Corporation (“SMC”) ( is a Nevada Corporation and is a privately held wholly owned subsidiary of PSYC that was incorporated on February 8, 2022. At present time, SMC operates as a multimedia service company for the medicinal psychedelic industry through Psychedelic Spotlight in addition to the developing community-based platform, Bonfire (f/k/a “PsycheDev”). However, management intends, but cannot guarantee the success or profitability, that the business plan for SMC is to potentially expand beyond the medicinal psychedelic industry by way of other multimedia-related opportunities within other niche-style industries like cannabis, health and wellness, and sports such that SMC can make use of the audience it is establishing, across its platforms for cross-promotional opportunities and with the intent of developing a network of interconnected media-focused platforms.

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19 and the success of the current vaccine distribution, the adverse effect of the Omicron variant, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC website and is not incorporated by reference into such reports.

Disclaimer: PSYC Corporation does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.

Source link

Continue Reading


Article: Gratefully Remembering The UK Microdot LSD of the 1970’s




This psychonaut remembers versions of these still knocking around in the early 1980’s. 5 sheets  made our live aid weekend in Brighton a very long one !


In the early 1970s, England was awash in LSD and much of it was produced by one clandestine organization: the Microdot Gang. Microdot LSD was known for its purity and for its potency. In fact, many users from the 1970s still remember it by name some fifty years later. At its apex in 1978, the Microdot Gangs’s autonomous distribution networks extended to Europe, Canada, Australia, and the United States. By the mid-1970s, British law enforcement made LSD distribution a top priority and launched Operation Julie, a massive investigation and sting operation that included hundreds of detectives and police officers. Operation Julie eventually led to 87 household raids and over 120 arrests in March of 1977. Alston Hughes, aka “Smiles,” a crucial LSD dealer for the Microdot gang, was arrested at his home in Llanddewi-Brefi, a remote and tranquil Welsh village. When the villagers heard of his arrest, they were shocked because Smiles was widely known for his affability and his fondness for buying free drinks at the local pub.

British law enforcement has typically regarded “Operation Julie” as an enormously successful sting operation that effectively curtailed the production of Microdot LSD. There have been nine books written about Operation Julie and many of them were written by detectives who participated in the historic investigation. Although the story of Operation Julie has often been dominated by law enforcement’s narrative of moral self-congratulation (“we took acid off the streets”), alternative histories of the Microdot era are now beginning to emerge.

Andy Roberts, noted historian of British psychedelic culture, has penned an engaging and thought provoking biography, In Search of Smiles, LSD, Operation Julie and Beyond (2023), that provides a lively portrait of the British counterculture in the 1970s. Recreating Hughes’s colorful life as a cannabis and LSD dealer in the halcyon days of the 1970s, In Search of Smiles succeeds because it mirrors the life experiences of many people who came of age in the golden era of British psychedelia (1960s and the early 1970s). In literary terms, Roberts’s narrative of Smiles’s topsy turvy life also succeeds as a Dickensian tale of deferred redemption: its protagonist endures horrific abuse from his sadistic Mancunian stepfather, yet he somehow manages to retain his good nature and humanity. While serving in the army, the abuse continues when Hughes is beaten by his superior officer, Lance Corporal Lunn: “[Hughes] bore the beatings stoically, I smiled at him and he called me “smiler,” a nickname he would carry for several years until his first wife shortened it to “Smiles.” After leaving the army, Smiles travels to free festivals (Bath Free Festival of Blues and Progressive Music in 1970, Phun City, and the iconic Isle of Wight festival) where he discovers community—like minded hippies and free spirits—as well as LSD and free love. By narrating the story of Hughes’s transformation, Roberts manages to also provide a vivid portrait of British alternative culture in the era before Thatcher comes to power.

Read the interview

Gratefully Remembering Microdot LSD in the Seventies

Source link

Continue Reading


Ketamine Healthcare via Enthea; Now Nationwide




Ketamine is one of the up-and-comers in the new hallucinogen craze that’s taking over; and it just got pushed to a whole new level. According to recent reports, ketamine is now offered by healthcare provider Enthea, throughout the entire US.

A bit about ketamine and hallucinogens

First off, ketamine isn’t a psychedelic. It’s often classified that way today, as a means of simplifying for the public, what is actually a complicated categorization system of drugs. There are different kinds of hallucinogens, and psychedelics are one grouping. However this grouping only consists of LSD, DMT, psilocybin, and mescaline. Though MDMA is often included in this group, its technically classified as a psychostimulant. These drugs (psychedelics and MDMA) are specifically known to cause an agonist response at serotonin receptors; which means they raise the amount of serotonin in the system.

Ketamine is classified as a dissociative hallucinogen, along with drugs like PCP and DXM. These drugs have a primary action as antagonists at NMDA receptors, among other actions. The other official grouping of hallucinogens, is deliriants; a classing which involves plants like datura, and compounds like scopolamine, or even the allergy medicine Benadryl. These are all anticholinergics, which means they have an antagonistic effect at acetylcholine receptors, and decrease acetylcholine in the system.

Ketamine is a synthetic, lab-made drug, which was formulated in 1962 by the pharmaceutical company Parke-Davis. The idea was to find a powerful anesthetic, which didn’t cause damage, or lower vital body processes; like blood pressure, or breathing rates. Ketamine works as a sedative, but not as a hypnotic; meaning it makes a person drowsy, without putting them to sleep. It causes what’s described as “electrophysiological and functional dissociation between thalamocortical and limbic systems.” In my personal experience it quite literally feels like the parts of the brain are moving away from each other.

Enthea healthcare provides clinic and at-home ketamine therapy
Enthea healthcare provides clinic and at-home ketamine therapy

Unlike a lot of the drugs we speak about here, ketamine is not a Schedule I compound. In fact, it’s a Schedule III compounds, legal for medical use as an anesthetic in humans and animals. However, as per FDA rules for off-label prescribing; wherein a drug can be prescribed by a physician for uses other than what its officially cleared for; ketamine has been at the center of a growing gray medical market. Legal by off-label prescribing, but with no governmental regulation for what its being used for.

This loophole spawned an entire industry of clinics that offer treatments for pain and different psychological disorders. And patients don’t need to worry about their primary care physician (or specialist) giving them a prescription; they can get it directly from the clinic. This is a major benefit, as individual doctor opinions do not update at the same speeds.

Ketamine now offered as healthcare throughout US

Gray markets present an issue for government bodies. Unlike defined black markets, they aren’t necessarily illegal; in fact, by definition, they’re not. But they’re also not legal markets, which means they’re hard to go after legally, but they also provide no additional tax benefit to regulating bodies. As such, regulating bodies either want to get rid of them (think vapes and cannabinoids), or formally regulate them. Currently with ketamine, there’s a standstill; and this is being taken advantage of by Enthea Healthcare.

I’ve covered Enthea before, and its pioneering efforts to provide ketamine as a basic healthcare benefit. The company is the first licensed workplace healthcare provider for psychedelic therapies, and plans to utilize other hallucinogens for treatment upon their approval. Due to recently closed deals, Enthea expanded out to the point of now offering this coverage nationwide.

I reported last year that Enthea partnered with Dr. Bronner’s, making for the first offering of ketamine therapy as a part of worker healthcare. In late summer, Enthea released a progress report indicating that so far these ketamine treatments have been used by a small percentage of the staff, and provided positive benefits.

As per its report: 7% of Dr. Bronner’s staff utilized ketamine services since their initiation into the healthcare program. Initial reporting indicates that workers experiencing PTSD, general anxiety issues, or major depressive disorder, reported improvements of 86%, 65%, and 67% respectively. While no one said ketamine treatments will help everyone; imagine the possible improvement if these percents are relevant across an entire population’s use.

Employment healthcare options to treat stress and depression
Employment healthcare options to treat stress and depression

Now, Enthea is expanding its coverage further with new deals. According to Live5News, Enthea’s new deals are with the clinic chains Skylight Psychedelics and Innerwell. Both provide ketamine therapy throughout the US, which expands Enthea’s reach. The first, offers treatments in its Skylight Journey Centers, as well as at-home treatments, for those who prefer not to be in a clinic.

The second, Innerwell, provides therapy as a combination approach; involving a team of holistic therapists, along with standard medical approaches, and coaching. The company seeks to use data and patient outcomes, to drive the direction of treatment. This company also provides in-house and at-home services.

What does a company need to do to offer these services to their workers? Simply add it on to the plan, as they would for dental or vision coverage. All the employer must do, is sign up. Enthea handles everything else, including: a providers network, established policy which includes standards of care, treatment authorization and reimbursement for companies, educational services, and specifically tailored plans for a company’s precise needs.

Sherry Rais, Enthea’s co-founder and CEO stated, “Nationwide availability represents a pivotal moment in accomplishing Enthea’s mission of helping employers with workplace mental health challenges. Our services at Enthea make it easy on businesses to embrace this safe and effective treatment offering for their employees and we’re proud to have the potential to impact the millions of people in the US living with mental health conditions.”

The problem of workplace depression

How necessary is it to find better treatments and services for employees? I suppose that’s a matter of opinion. Some people love getting up every day to navigate their work environment. Others cringe at the sound of each alarm; sickened by another day of office politics, possible bulling by bosses or peers, long work days away from family, and feelings of being overworked and underpaid. Let’s take a closer look at the issue of workplace depression.

According to an American Psychological Association 2021 Work and Well-being Survey, 59% of respondents said that just within the past month, their work was impacted by work-place stress. A huge 87% said they believe that better handling by employers could reduce mental health issues in workplace environments.

Employers can institute a benefits policy they think is best for workers
Employers can institute a benefits policy they think is best for workers

Further to this, a CDC informational page on workplace depression, states that depression causes a loss of 200 million working days a year, combined. This overall costs employers approximately $17 – $44 billion yearly. Depression issues lead to missed work days, and simply not being present or productive while at work.

According to NORC in conjunction with University of Chicago’s National Safety Council; “employers that support mental health see a return of $4 for every dollar invested in mental health treatment.” This indicates that if employers are more thoughtful of their employee’s issues and mindsets; they can improve their own spending, and essentially, waste less.

What jobs cause the most stress? According to the CDC, 10.8% of personal care and service workers report workplace stress, making for the highest stress jobs. Food industry workers clock in at 10.3% who experience stress. Lower stress jobs such as engineering, architecture, and surveying, report that only about 4.3% of employees are stressed.

Life, physical, and social science workers also experience lower stress, at a rate of 4.4%; the same as installation, maintenance, and repairmen. Of course, not everyone understands the concept of their own depression, or wants to admit to it in any context, given the massive stigma attached. I expect these numbers are actually incredibly low for these reasons of possible skewed reporting.

The National Safety Council, for its part, contributes that mental health issues among workers accounts for an extra $3,000 yearly per worker in healthcare services; and that the cost for days lost to stress-related issues is $4,783 per employee, every year. It’s a bad cycle. Stress issues lower worker ability, which means employers lose out as well. Perhaps this makes them then put more stress on employees.


So far, the broad use of ketamine therapy for workplace employees is still a new and growing concept. With the help of Enthea, however, it can now be utilized by any employer in the US who wants to offer ketamine, and other psychedelic treatments, as they become available. If you are an employer, and you want to offer your employees these services, go here. And if you’re an employee who wants coverage of these services; you’ll soon have a growing number of workplaces offering it. Just hold tight.

Hey there drug aficionados! Thanks for making your way to We’re an independent publication in the drug space, here to bring you cutting-edge reporting every day. Don’t be a stranger; join us regularly for updates; and sign up to the Cannadelics Weekly Newsletter, so you’re never late to get the news.

Source link

Continue Reading

estrogen and psilocybin

How Estrogen Alters Psilocybin’s Effects




The numerous benefits of psychedelics have been coming to light in recent years, and women are taking notice. With little options in the way of pharmaceutical drugs, especially when it comes to treating mental illness and hormonal imbalances, it’s no surprise that women are experimenting with hallucinogens to see what can actually help. And better yet, a recent study found that psilocybin can help regulate menstrual issues. Let’s dig deeper into how and why psychedelics are so valuable for the fairer sex.

Women and psychedelics 

The psychedelic renaissance is in full swing, and women are at the heart of it. After decades of prohibition and condemnation (following a brief period of them being studied and used medicinally), the western world is finally starting to reexamine the many therapeutic benefits of these substances. LSD, Ketamine, MDMA, and psilocybin have been undergoing various clinical trials to see how they can be utilized to address a growing mental health crisis in the United States.  

Jennifer Gural, a psychotherapist from Los Angeles, California, commented about how hallucinogens have helped change her life, and how she began using them to help her female patients as well. “It shifted the focus of my life,” she stated. “It really helped me to tackle how my brain works and how I was thinking … It was such a profoundly life-changing experience. I have done ayahuasca and I’ve done psilocybin. I don’t know if I’ll ever do it again, but I’m open to that if it’s needed—which I think is how we should use psychedelics.”  

While there seems to be a recent influx of ladies trying psychedelics, self-medicating is nothing new for women. This could stem from frustrations with our existing health-care system, and how it has been historically geared toward treating men and either dismissing our issues or over-medicating us.  

As women – daughters, mothers, sisters, grandmothers, wives, friends – we have many struggles that we are often forced to face alone. Women are more likely to suffer from PTSD than men – particularly women of color, transgender, and gender-diverse individuals. Women also deal with depression and anxiety more often, and one in seven women have postpartum depression after childbirth.  

New studies have found that even a couple experiences with psychedelics, especially when combined with talk therapy, can lead to lifechanging, psychological developments. As a matter of fact, MDMA and psilocybin have been labeled as “breakthrough therapies” by the FDA, a designation given to “promising drugs proposed to fill an unmet need”. With so many pharmaceutical antidepressant and antianxiety drugs on the market, and the number of mental disorders still rising, we can clearly see that treating our troubled human minds is that unmet need.  

Is this the beginning of a brighter, more beautiful future for women’s healthcare? One where common mental illnesses, chronic pain, and hormonal conditions are treated successfully with psychedelic trips, rather than a lifetime of pharmaceutical medications? It seems quite promising.  

The new research on psilocybin and estrogen 

Although no clinical trials have been conducted, researchers from John Hopkins University have been looking over case files and anecdotal reports on women and psychedelics, and how estrogen can change the effects of psilocybin specifically. We know that estrogen can impact binding at serotonin receptor sites, and because most hallucinogens interact with serotonin receptors as well, experts believe that our cycles can influence how psilocybin works in our bodies, and vice versa, the psilocybin itself can have an impact on our hormones.  

Based on the aforementioned case studies, researchers discovered that psilocybin seemed to help regulate menstrual cycles. One of the women studied had premenstrual dysphoric disorder, which is a very severe form of PMS, and she used psilocybin to help regulate it. In another case, a woman suffered from polycystic ovarian syndrome and was having irregular periods. At one point, menstruation completely stopped for a while, but after taking psilocybin, it came back.  

“Our menstrual cycles occur along the hypothalamic-pituitary-gonadal (HPG) axis, so as one hormone kicks off, it tells another hormone what to do in this feedback loop and that’s the trajectory of our menstrual cycles,” says Jennifer Chesak, author of The Psilocybin Handbook for Women. “We also have the axis that manages our stress response, the hypothalamic-pituitary-adrenal (HPA) axis. These two axes sort of overlap, and so they each impact one another. When we use psilocybin, we are at doing something along that stress response along the HPA axis.” 

Chesak added: “We already know from research outside of psychedelics, that these two axes do impact each other: our stress response can impact our cycle, and our cycles can impact our stress response. So, it’s not a stretch to think that when we are using psilocybin, that something is going on with our stress response that then impacts the menstrual cycle” 

Although we only have these few case studies and anecdotal reports at the moment, the results are telling. And it begs the question of when we can see a real clinical trial on this topic, so we can better understand the mechanisms of how it works from a scientific perspective. 

Aside from medical benefits, do women experience psychedelics differently than men? 

Honestly, who really knows? Obviously, no studies have been done on whether women trip differently than men. But it’s possible that because women tend to be more emotional, empathetic, and receptive to spiritual experiences – this could be beneficial to producing better and more positive, even more therapeutic highs.  

Historically, statistics indicate that men use more drugs than women – and this across the board, from illicit drugs to legal substances like tobacco and alcohol. And since most research is still conducted on male subjects, female drug use patterns and their subsequent experiences remain somewhat of an enigma.  

However, we do know that in general, psychotropic drugs impact women differently than men, but sex-based responses to medications are often overlooked. It wasn’t until the 1990s that women were even allowed to participate in clinical trials in the United States, and many studies are still done using a larger number of male participants.  

Despite this, women are twice as likely as men to be prescribed psychotropic medication (back to that overmedicating issue), and recent research shows that factors like different hormones, body composition, and metabolism can cause different drug-reactions. For example, the sleep medication Ambien was found to be twice as potent for women.  

Additionally, experts claim that women are “between 50 and 75 percent more likely to experience side effects”. An analysis of existing clinical trials published June 5, 2020, in the journal Biology of Sex Differences, authored by Prendergast and Irving Zucker of UC Berkley, they noted 86 drugs which presented “clear evidence of sex differences in how the body broke down the drug.” They found that “For nearly all of these drugs, women metabolized them more slowly than men, leading to higher levels of exposure to the drug; in 96% of cases, this resulted in significantly higher rates of adverse side effects in women.” 

Final thoughts 

To reiterate, because the foundation of modern medicine is structured around research performed almost exclusively on men, most of what science tells us about the prevention, diagnosis, and treatment of illness may not be applicable to women. With so much of our population feeling like they are not understood by healthcare professionals, it’s no surprise that a growing number of women are self-medicating with cannabis, psychedelics, and other natural, alternative solutions.

As we learn more about how psilocybin and other hallucinogens interact with female hormones, we can better understand how to use these incredible products to improve our health, and our lives.  

Welcome cannabis aficionados! Thanks for making your way to, an independent news site going deep into the worlds of cannabis, psychedelics, and well beyond. We’re big on updates, so come by regularly. And get yourself signed up to the Cannadelics Weekly Newsletter, for the best in related product offerings, as well.

Source link

Continue Reading


Copyright © 2021 The Art of MaryJane Media